These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 15368916)
1. Model based on GRID-derived descriptors for estimating CYP3A4 enzyme stability of potential drug candidates. Crivori P; Zamora I; Speed B; Orrenius C; Poggesi I J Comput Aided Mol Des; 2004 Mar; 18(3):155-66. PubMed ID: 15368916 [TBL] [Abstract][Full Text] [Related]
2. Multivariate modeling of cytochrome P450 3A4 inhibition. Kriegl JM; Eriksson L; Arnhold T; Beck B; Johansson E; Fox T Eur J Pharm Sci; 2005 Apr; 24(5):451-63. PubMed ID: 15784335 [TBL] [Abstract][Full Text] [Related]
3. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. Shen M; Xiao Y; Golbraikh A; Gombar VK; Tropsha A J Med Chem; 2003 Jul; 46(14):3013-20. PubMed ID: 12825940 [TBL] [Abstract][Full Text] [Related]
4. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. Kriegl JM; Arnhold T; Beck B; Fox T J Comput Aided Mol Des; 2005 Mar; 19(3):189-201. PubMed ID: 16059671 [TBL] [Abstract][Full Text] [Related]
5. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Balakin KV; Ekins S; Bugrim A; Ivanenkov YA; Korolev D; Nikolsky YV; Skorenko AV; Ivashchenko AA; Savchuk NP; Nikolskaya T Drug Metab Dispos; 2004 Oct; 32(10):1183-9. PubMed ID: 15231683 [TBL] [Abstract][Full Text] [Related]
6. Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Emoto C; Murayama N; Rostami-Hodjegan A; Yamazaki H Curr Drug Metab; 2010 Oct; 11(8):678-85. PubMed ID: 20973757 [TBL] [Abstract][Full Text] [Related]
7. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Wanchana S; Yamashita F; Hashida M Pharm Res; 2003 Sep; 20(9):1401-8. PubMed ID: 14567634 [TBL] [Abstract][Full Text] [Related]
8. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. Manga N; Duffy JC; Rowe PH; Cronin MT SAR QSAR Environ Res; 2005; 16(1-2):43-61. PubMed ID: 15844442 [TBL] [Abstract][Full Text] [Related]
9. Predicting blood-brain barrier permeation from three-dimensional molecular structure. Crivori P; Cruciani G; Carrupt PA; Testa B J Med Chem; 2000 Jun; 43(11):2204-16. PubMed ID: 10841799 [TBL] [Abstract][Full Text] [Related]
10. In silico prediction of cytochrome P450 2D6 and 3A4 inhibition using Gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. Jensen BF; Vind C; Padkjaer SB; Brockhoff PB; Refsgaard HH J Med Chem; 2007 Feb; 50(3):501-11. PubMed ID: 17266202 [TBL] [Abstract][Full Text] [Related]
11. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries. Jenkins KM; Angeles R; Quintos MT; Xu R; Kassel DB; Rourick RA J Pharm Biomed Anal; 2004 Mar; 34(5):989-1004. PubMed ID: 15019033 [TBL] [Abstract][Full Text] [Related]
12. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Crespi CL; Penman BW Adv Pharmacol; 1997; 43():171-88. PubMed ID: 9342176 [TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026 [TBL] [Abstract][Full Text] [Related]